DUBLIN–(BUSINESS WIRE)–The “Alzheimer’s Therapeutics Market Share, Size, Trends By Drug Class, By Distribution Channel, By Region, Segment Forecast, 2022 – 2030” report has been added to ResearchAndMarkets.com’s offering.
The global alzheimer’s therapeutics market size is expected to reach USD 14.20 billion by 2030, according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
Alzheimer’s disease is a degenerative neurological condition where memory loss and cognitive impairment are brought on by the death of brain cells. As the brain shrinks, intellectual, social, and behavioral abilities gradually deteriorate. It is the most frequent cause of dementia.
Alzheimer’s accounts for 60-70% of all cases of dementia, making it the most prevalent type. Government and non-government organizations are investing extensively in the development of diagnostics and therapies for the disease as a result of the rising prevalence of the disease worldwide, which could help the industry grow. According to the World Health Organization, the economic cost burden is huge, ranging from USD 1.3 trillion to 2.8 trillion by 2030.
The patient’s family, society, and the economy are all severely impacted by AD. Both the illness and its mechanism are complex. Given the increase in AD incidence globally, certain research has shown the necessity to create an effective therapy. Memantine and acetylcholinesterase inhibitors are the only medications used to treat this condition, despite the fact that it has been studied for more than a century.
The industry for this disease therapeutics would expand as R&D investments by biopharmaceutical firms increased. Additionally, the development of novel therapies to treat, sluggish, and prevent disease, as well as early Alzheimer’s disease diagnosis, will create prospects for the worldwide market for disease therapeutics.
The industry is expanding as a result of rising healthcare awareness and new Alzheimer’s disease diagnostic technologies. Due to the rising frequency of disease, there has been a rise in the use of medicines for the condition recently. The demand for such disease medicines is expanding as a result of an aging population, rising healthcare costs, and greater government spending.
Alzheimer’s Therapeutics Market Report Highlights
- Cholinesterase Inhibitors segment is anticipated to grow at a lucrative CAGR over the forecast period owing to the frequently recommended to treat symptoms linked to memory, thinking, language, judgment, and other application
- Retail Pharmacies segment is expected to hold the significant revenue share over the forecast period due to the easy access and availability of drugs and therapies for Alzheimer’s treatment.
- North America is expected to grow at a significant CAGR rate over the projected period on account of the rapidly increasing ageing population, significant investment in research and development activities, and the introduction of new products
The publisher has segmented the alzheimer’s therapeutics market report based on drug class, distribution channel, and region:
Alzheimers Therapeutics, Drug Class Outlook (Revenue – USD Billion, 2018 – 2030)
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Manufactured Combination
Alzheimers Therapeutics, Distribution Channel Outlook (Revenue – USD Billion, 2018 – 2030)
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Alzheimers Therapeutics, Regional Outlook (Revenue – USD Billion, 2018 – 2030)
- North America
- U.S
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Netherlands
- Asia Pacific
- China
- India
- Japan
- South Korea
- Indonesia
- Malaysia
- Latin America
- Argentina
- Brazil
- Mexico
- Middle East & Africa
- UAE
- Saudi Arabia
- Israel
- South Africa
Companies Mentioned
- Teva Pharmaceuticals Ltd.
- Eisai Co. Ltd.
- AbbVie Inc.
- Amneal Pharmaceuticals Inc.
- Macleods Pharmaceuticals Ltd.
- Viatris Inc.
- Lupin Ltd.
- Cipla Ltd.
- Torrent Pharmaceuticals ltd.
- Unichem laboratories ltd.
- Lannett Inc.
- Janssen Pharmaceuticals Inc. (Johnson & Johnson)
- Novartis AG
- Zydus Lifesciences Ltd (CADILA)
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Aurobindo
For more information about this report visit https://www.researchandmarkets.com/r/69lycq
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900